Literature DB >> 22974514

How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring.

Priya Bahri1, Mira Harrison-Woolrych.   

Abstract

Over the past decade, the annual meetings of national centres participating in the WHO Programme for International Drug Monitoring have increasingly included discussions on how to improve communication between national pharmacovigilance centres, patients, healthcare professionals, policy makers and the general public, with the aim of promoting the safe use of medicines. At the most recent meetings, working groups were dedicated to discuss possible applications and implementation of social marketing and patient-tailored approaches. This article provides the history and a summary of the recent discussions and recommendations to support progress in this respect at national and global level. Recommendations are made to investigate and pilot these approaches in small-scale projects at national pharmacovigilance centres. Applying elements from the social marketing and patient-tailored approaches to support behaviours of safe medicines use in patients and healthcare professionals should give the pharmacovigilance community new tools to achieve their goal to minimize risks with medicines and improve patient safety.

Entities:  

Mesh:

Year:  2012        PMID: 22974514     DOI: 10.2165/11640530-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  9 in total

Review 1.  The public health implications of the 1995 'pill scare'.

Authors:  A Furedi
Journal:  Hum Reprod Update       Date:  1999 Nov-Dec       Impact factor: 15.610

2.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

Authors:  P Pouyanne; F Haramburu; J L Imbs; B Bégaud
Journal:  BMJ       Date:  2000-04-15

3.  Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies.

Authors:  H J M Beijer; C J de Blaey
Journal:  Pharm World Sci       Date:  2002-04

4.  Adverse drug reaction monitoring--cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission.

Authors:  M Goettler; S Schneeweiss; J Hasford
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

5.  Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.

Authors:  N Muehlberger; S Schneeweiss; J Hasford
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

Review 6.  Which drugs cause preventable admissions to hospital? A systematic review.

Authors:  R L Howard; A J Avery; S Slavenburg; S Royal; G Pipe; P Lucassen; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06-26       Impact factor: 4.335

7.  Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands.

Authors:  Anne J Leendertse; Antoine C G Egberts; Lennart J Stoker; Patricia M L A van den Bemt
Journal:  Arch Intern Med       Date:  2008-09-22

8.  Retrospective analysis of mortalities associated with medication errors.

Authors:  J Phillips; S Beam; A Brinker; C Holquist; P Honig; L Y Lee; C Pamer
Journal:  Am J Health Syst Pharm       Date:  2001-10-01       Impact factor: 2.637

9.  Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis.

Authors:  Katja M Hakkarainen; Khadidja Hedna; Max Petzold; Staffan Hägg
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

  9 in total
  3 in total

1.  Community pharmacy staff perceptions on preventing alcohol and medication interactions in older adults.

Authors:  Faika Zanjani; Lauren Crook; Rachel Smith; Demetra Antimisiaris; Nancy Schoenberg; Catherine Martin; Richard Clayton
Journal:  J Am Pharm Assoc (2003)       Date:  2016 Sep-Oct

2.  Governance and pharmacovigilance in Brazil: a scoping review.

Authors:  Kathy Moscou; Jillian C Kohler; Anita MaGahan
Journal:  J Pharm Policy Pract       Date:  2016-02-08

3.  Pharmaceutical company perspectives on current safety risk communications in Japan.

Authors:  Hisashi Urushihara; Gen Kobashi; Hideaki Masuda; Setsuko Taneichi; Michiko Yamamoto; Takeo Nakayama; Koji Kawakami; Tsutomu Matsuda; Kaori Ohta; Hiroki Sugimori
Journal:  Springerplus       Date:  2014-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.